Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,136 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,136 Papers indexed
1,440 Papers AI scored
40,136 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-06 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40136 results
C
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Benefits, Problems, and Motivations for Using the Online Patient Portal in Adolescent Oncology: Interviews With Adolescents and Parents.
PMID 40623280 Published: 2025-07-07 Ingested: 2026-08-02 12:04 AM JCO clinical cancer informatics
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Risk of neurodevelopmental disorders in the offspring of mothers with a history of endometriosis in Taiwanese women.
PMID 40620707 Published: 2025-06-20 Ingested: 2026-08-02 12:04 AM Brain, behavior, & immunity - health
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
The Relationship Between the Health Literacy Levels of Women of Reproductive Age and Their Level of Knowledge About Cancer Screenings.
PMID 40618412 Published: 2025-08-01 Ingested: 2026-08-02 12:05 AM Journal of evaluation in clinical practice
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Hepatoblastoma regional trends: dynamic SDI & joinpoint regression analysis.
PMID 40618033 Published: 2025-07-05 Ingested: 2026-08-02 12:04 AM BMC cancer
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Evaluating modified ACR TI-RADS nodule size for thyroid nodules in pediatric population.
PMID 40615946 Published: 2025-07-04 Ingested: 2026-08-02 12:04 AM BMC medical imaging
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Factors modulating the post-operative course in minimally invasive and open pediatric nephrectomy for non-malignant indications.
PMID 40603228 Published: 2025-06-17 Ingested: 2026-08-02 12:04 AM Journal of pediatric urology
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Periapical lesions: Assessment of clinical diagnostic accuracy and prevalence of nonendodontic lesions mimicking endodontic pathoses.
PMID 40598469 Published: 2025-07-01 Ingested: 2026-08-02 12:04 AM International endodontic journal
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

C
Are home practices safe? Furan mitigation in infant food handling.
PMID 40597467 Published: 2025-06-04 Ingested: 2026-08-02 12:04 AM Food research international (Ottawa, Ont.)
AI -
Standard 56.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 56.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 2403 of 3345
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic